查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1593746

重度忧郁症市场评估：按药物类别、分销管道和地区划分的机会和预测（2017-2031）

Major Depressive Disorder Market Assessment, By Drug Classes, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 228 Pages | 商品交期: 3-5个工作天内

价格

全球重度忧郁症 (MDD) 市场规模预计将从 2023 年的 122.5 亿美元成长到 2031 年的 166.8 亿美元，预测期内复合年增长率为 3.93%。

重度忧郁症是一种常见且严重的精神疾病，其特征是持续悲伤、绝望感以及对日常活动缺乏兴趣或乐趣。它还会影响您的睡眠、食慾和整体功能。治疗选择包括心理治疗（如认知行为疗法）、抗忧郁药物如选择性血清素再摄取抑制剂（SSRIs）和血清素去甲肾上腺素再摄取抑制剂（SNRIs）以及生活方式改变（如运动和营养）等。在某些情况下，可以使用经颅磁刺激（TMS）和电惊厥疗法（ECT）等先进治疗方法。由于各种类型的发展，用于治疗重度忧郁症的药物和医疗器材市场预计在预测期内将成长。增加市场投资、监管机构的举措以及各利益相关者为提高市场成长率而共同努力也预计将在未来几年带来重大变化。

该报告调查了全球重度忧郁症市场，并提供了市场定义和概述、市场规模趋势和预测、各个细分市场/地区/主要国家的详细分析、行业结构以及对市场成长的影响。分析、案例研究、竞争格局、主要公司简介等

目录

第1章 专案范围与定义

第2章 研究方法

第3章 执行摘要

第4章 全球重度忧郁症市场展望

  • 市场规模分析与预测
  • 市占率分析/预测
    • 按药物类别
    • 按分销渠道
    • 按地区
    • 公司市场占有率分析
  • 市场地图分析

第5章 北美重度忧郁症市场展望

  • 市场规模分析与预测
  • 市占率分析/预测
  • 国家市场评估
    • 美国
    • 加拿大
    • 墨西哥

第6章欧洲重度忧郁症市场展望

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 土耳其
  • 波兰

第7章亚太地区重度忧郁症市场展望

  • 印度
  • 中国
  • 日本
  • 澳洲
  • 越南
  • 韩国
  • 印尼
  • 菲律宾

第8章 南美洲重度忧郁症市场展望

  • 巴西
  • 阿根廷

第9章 中东和非洲重度忧郁症市场前景

  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第10章 供需分析

第11章 进出口分析

第12章 价值链分析

第13章 波特五力分析

第14章 PESTLE分析

第15章价格分析

第16章 市场动态

  • 市场驱动力
  • 市场课题

第17章市场趋势与发展

第18章法律与监管架构/创新

  • 临床试验
  • 监管审批
  • 管道概览

第19章 专利情况

第20章案例研究

第21章 竞争格局

  • 前 5 名市场领导者的竞争矩阵
  • 前5名企业SWOT分析
  • 前10名企业现状
    • Viatris Inc.
    • AbbVie Inc.
    • Abbott Laboratories
    • Aurobindo Pharma, Inc.
    • Teva Pharmaceuticals, Inc.
    • Sun Pharmaceuticals Industries Ltd.
    • Pfizer Inc.
    • Eli Lilly and Company
    • Otsuka Pharmaceutical Co., Ltd.
    • Takeda Pharmaceuticals Company Limited

第22章 战略建议

第23章 关于我们公司/免责声明

Product Code: MX12258

Global major depressive disorder market stood at USD 12.25 billion in 2023 and is expected to reach USD 16.68 billion by 2031, growing at a CAGR of 3.93% during the forecast period. Major depressive disorder is a common and serious mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in daily activities. It can affect sleep, appetite, and overall functioning. Treatment options include psychotherapy (such as cognitive-behavioral therapy), antidepressant medications like Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), and lifestyle changes (including exercise and nutrition). In some cases, advanced treatments like transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT) may be considered resistant cases. The market for pharmaceuticals and medical devices used to treat MDD is anticipated to grow during the forecast period due to various types of development, such as growing emphasis and clinical implications around mental health. Along with that, growing investments in the market, regulatory initiatives, and combined efforts of various stakeholders to boost the market's growth rate are anticipated to make huge changes in the future.

In August 2023, Biogen Inc. and Sage Therapeutics, Inc. announced the approval of ZURZUVAE (zuranolone) 50 mg by the US Food and Drug Administration (FDA). This medication is designed to treat postpartum depression (PPD) in adults. ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can rapidly improve depressive symptoms in women with PPD. Additionally, the FDA has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for zuranolone in the treatment of adults with major depressive disorder.

Biogen Inc. and Sage Therapeutics, Inc. announced the approval of ZURZUVAE (zuranolone) 50 mg by the US Food and Drug Administration (FDA). This medication is designed to treat postpartum depression (PPD) in adults. ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can rapidly improve depressive symptoms in women with PPD. Additionally, the FDA has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for zuranolone in the treatment of adults with major depressive disorder.

Rising Cases and Emphasis on Mental Health to Boost Market Demand

Major depressive disorder cases have been on the rise recently, which tends to elevate market demand for mental health solutions. The new understanding of mental health issues today eliminates the stigma while encouraging more individuals to seek treatment. Healthcare providers and pharmaceutical companies tend to concentrate their efforts on innovative therapies and holistic approaches, including psychotherapy, digital health solutions, and new treatments. The COVID-19 pandemic has also increased mental health issues. The cases of reported depression are on the rise, and effective interventions require better programs for mental health. Government initiatives towards increasing mental health program funding have also helped fuel this growth. As there is more understanding about mental health, the demand for more tailored and accessible options for treatment will drive the market towards significant growth over the next few years.

For instance, according to an article published in Signal Transduction and Targeted Therapy Journal in February 2024, the prevalence of depression is increasing every year. Approximately 300 million people worldwide are affected by major depressive disorder, making it one of the leading causes of disability. In 2018, MDD ranked third in terms of disease burden according to the World Health Organization (WHO), and it is predicted to become the leading cause by 2030.

Government Initiatives to Major Depressive Disorder Drives Market Growth

With the increasing interest of investors in the treatment of major depressive disorder, business increases due to higher investment in research and development of new treatments, such as pharmaceuticals and digital health solutions. With increased innovation rates, this more rapidly delivers greater diversity and effectiveness in therapies as well as personalization of treatment. Companies respond to the increased demand by offering more products, while competition helps bring down costs, enhancing patient care access. In addition, investors tend to encourage collaboration between biotechnology firms, research institutions, and healthcare delivery systems, which maximizes resource sharing and enhances research. Investment in the issues of mental health increases public awareness of mental illness, and the stigmatism associated with the conditions is reduced. Therefore, more individuals can receive help with mental health disorders.

For instance, in July 2024, Autobahn Therapeutics, Inc., a biotech company established from a lab at Oregon Health & Science University, secured USD 100 million in private investment to develop treatments for neuropsychiatric disorders like major depressive disorder and bipolar depression. The funding will advance their pipeline of brain-penetrant small molecules, including a compound targeting major depressive and bipolar depression disorders, which affect over 27 million people in the United States.

Drug Segment Dominates with High Market Share

The dominance of the drug segment in the major depressive disorder market relates to its accessible treatments. The application areas of pharmacological treatments, especially antidepressants of the SSRIs and SNRIs class, are broad in this area. Accessibility is a contributing factor to relatively higher patient adoption rates. Novel drug developments continue to create new formulations and targeted therapy forms that optimize treatment options and attract investments. Moreover, the high prevalence of MDD calls for medication, as most of them are yet to be relieved from the debilitating symptoms. Additionally, medication has been considered the first-line treatment for most healthcare providers, especially in moderate to severe cases, leading to strong market penetration. Regulatory approvals in the market further fuel the growth of the market share of the drug segment.

For instance, in September 2023, Fabre-Kramer Pharmaceuticals Inc., a biopharmaceutical company dedicated to psychiatry and neurology treatments, announced the US FDA approval of its Exxua, a gepirone hydrochloride extended-release tablet intended for the treatment of major depressive disorders in adults. Exxua represents a new class of antidepressants; it is the first and only approved antidepressant with a novel mechanism of action that selectively targets the serotonin 1A receptor, a key regulator of mood and emotion.

North America Dominates Major Depressive Disorder Market

North America holds a dominant position in the major depressive disorder market due to several factors. Firstly, there is a high prevalence of depression, driven by increasing awareness and improved diagnosis, leading to more patients seeking treatment. The region boasts advanced healthcare infrastructure and access to a wide range of treatment options, including innovative therapies and medications. Significant investment in mental health research and development fosters the emergence of new and effective treatments. Major pharmaceutical companies are concentrated in North America, driving competition and innovation. The US FDA plays a crucial role by providing expedited approval pathways for new treatments, which enhances market responsiveness to emerging therapies.

In August 2024, Otsuka Precision Health, Inc. and Click Therapeutics, Inc. launched Rejoyn, the first prescription digital therapeutic for treating major depressive disorder symptoms. The US FDA approved it in March 2024, and it is available for adult patients with MDD aged 22 years and older who are on antidepressant medication. Patients can obtain a prescription for Rejoyn from their current provider or via a virtual consultation from Wheel Health, Inc. BlinkRx is the exclusive pharmacy provider for Rejoyn.

Future Market Scenario (2024-2031F)

Innovative novel drugs that are still in the development stages can expand the major depressive disorder market greatly by establishing innovative lines of treatment, such as efficiency and reduced side effects. Advances in new antidepressants, including fast-acting ketamine and psychedelic chemicals, also give hope to patients who are resistant to conventional treatment options. Such developments improve a patient's outcome and expand the treatment scope, thereby attracting funding and investment for research purposes. In addition, the rising wave of personalized medicine approaches that use genetic and biomarker information in tailoring treatments will further increase the precision of MDD interventions. More advanced innovations regarding understanding the disorder will lead to earlier diagnosis and effective management strategies. Every time a new treatment enters the market, it increases competition and lowers costs, making it available for wider patient populations.

For instance, in July 2024, Johnson & Johnson Services, Inc. submitted a supplemental New Drug Application (sNDA) to the US FDA. They are seeking approval for SPRAVATO (esketamine) CIII nasal spray as a monotherapy for adults with treatment-resistant depression (TRD). It's worth noting that nearly 30% of the estimated 280 million people worldwide living with major depressive disorder have TRD. TRD occurs when there is an inadequate response to two or more oral antidepressants during the same depressive episode.

Key Players Landscape and Outlook

The market for major depressive disorder is segmented into drugs mainly. The drug market is quite fragmented, with a huge number of players, while the device market is quite consolidated and has a lower share in terms of revenue. Recent market activities include mergers and acquisitions along with innovative product launches.

In August 2024, AbbVie Inc. completed its acquisition of Cerevel Therapeutics Holdings, Inc., enhancing its neuroscience portfolio, particularly in treating major depressive disorder (MDD). Cerevel's pipeline includes CVL-354, a potential kappa opioid receptor antagonist aimed at improving efficacy and tolerability for MDD. This acquisition aligns with AbbVie's strategy to address significant unmet needs in neurological and psychiatric conditions, promising advancements in therapies for patients suffering from these disorders.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Major Depressive Disorder Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Drug Class
      • 4.2.1.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
        • 4.2.1.1.1. Citalopram
        • 4.2.1.1.2. Escitalopram
        • 4.2.1.1.3. Fluoxetine
        • 4.2.1.1.4. Fluvoxamine
        • 4.2.1.1.5. Paroxetine
        • 4.2.1.1.6. Sertraline
      • 4.2.1.2. Selective Norepinephrine Reuptake Inhibitors (SNRIs)
        • 4.2.1.2.1. Desvenlafaxine Succinates
        • 4.2.1.2.2. Duloxetine
        • 4.2.1.2.3. Levomilnacipran
        • 4.2.1.2.4. Venlafaxine
        • 4.2.1.2.5. Bupropion
        • 4.2.1.2.6. Mirtazapine
        • 4.2.1.2.7. Trazodone
      • 4.2.1.3. Monoamine Oxidase Inhibitors (MAOIs)
        • 4.2.1.3.1. Phenelzine
        • 4.2.1.3.2. Tranylcypromine
        • 4.2.1.3.3. Antipsychotics
        • 4.2.1.3.4. Lithium Carbonate
        • 4.2.1.3.5. Aripiprazole
        • 4.2.1.3.6. Brexipiprazole
        • 4.2.1.3.7. Quetiapine
      • 4.2.1.4. Others
    • 4.2.2. By Distribution Channel
      • 4.2.2.1. Hospital Pharmacies
      • 4.2.2.2. Retail Pharmacies
      • 4.2.2.3. Online Pharmacies
    • 4.2.3. By Region
      • 4.2.3.1. North America
      • 4.2.3.2. Europe
      • 4.2.3.3. Asia-Pacific
      • 4.2.3.4. South America
      • 4.2.3.5. Middle East and Africa
    • 4.2.4. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Drug Class
    • 4.3.2. By Distribution Channel
    • 4.3.3. By Region

5. North America Major Depressive Disorder Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Drug Class
      • 5.2.1.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
        • 5.2.1.1.1. Citalopram
        • 5.2.1.1.2. Escitalopram
        • 5.2.1.1.3. Fluoxetine
        • 5.2.1.1.4. Fluvoxamine
        • 5.2.1.1.5. Paroxetine
        • 5.2.1.1.6. Sertraline
      • 5.2.1.2. Selective Norepinephrine Reuptake Inhibitors (SNRIs)
        • 5.2.1.2.1. Desvenlafaxine Succinates
        • 5.2.1.2.2. Duloxetine
        • 5.2.1.2.3. Levomilnacipran
        • 5.2.1.2.4. Venlafaxine
        • 5.2.1.2.5. Bupropion
        • 5.2.1.2.6. Mirtazapine
        • 5.2.1.2.7. Trazodone
      • 5.2.1.3. Monoamine Oxidase Inhibitors (MAOIs)
        • 5.2.1.3.1. Phenelzine
        • 5.2.1.3.2. Tranylcypromine
        • 5.2.1.3.3. Antipsychotics
        • 5.2.1.3.4. Lithium Carbonate
        • 5.2.1.3.5. Aripiprazole
        • 5.2.1.3.6. Brexipiprazole
        • 5.2.1.3.7. Quetiapine
      • 5.2.1.4. Others
    • 5.2.2. By Distribution Channel
      • 5.2.2.1. Hospital Pharmacies
      • 5.2.2.2. Retail Pharmacies
      • 5.2.2.3. Online Pharmacies
    • 5.2.3. By Country Share
      • 5.2.3.1. United States
      • 5.2.3.2. Canada
      • 5.2.3.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Major Depressive Disorder Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Drug Class
          • 5.3.1.2.1.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
          • 5.3.1.2.1.1.1. Citalopram
          • 5.3.1.2.1.1.2. Escitalopram
          • 5.3.1.2.1.1.3. Fluoxetine
          • 5.3.1.2.1.1.4. Fluvoxamine
          • 5.3.1.2.1.1.5. Paroxetine
          • 5.3.1.2.1.1.6. Sertraline
          • 5.3.1.2.1.2. Selective Norepinephrine Reuptake Inhibitors (SNRIs)
          • 5.3.1.2.1.2.1. Desvenlafaxine Succinates
          • 5.3.1.2.1.2.2. Duloxetine
          • 5.3.1.2.1.2.3. Levomilnacipran
          • 5.3.1.2.1.2.4. Venlafaxine
          • 5.3.1.2.1.2.5. Bupropion
          • 5.3.1.2.1.2.6. Mirtazapine
          • 5.3.1.2.1.2.7. Trazodone
          • 5.3.1.2.1.3. Monoamine Oxidase Inhibitors (MAOIs)
          • 5.3.1.2.1.3.1. Phenelzine
          • 5.3.1.2.1.3.2. Tranylcypromine
          • 5.3.1.2.1.3.3. Antipsychotics
          • 5.3.1.2.1.3.4. Lithium Carbonate
          • 5.3.1.2.1.3.5. Aripiprazole
          • 5.3.1.2.1.3.6. Brexipiprazole
          • 5.3.1.2.1.3.7. Quetiapine
          • 5.3.1.2.1.4. Others
        • 5.3.1.2.2. By Distribution Channel
          • 5.3.1.2.2.1. Hospital Pharmacies
          • 5.3.1.2.2.2. Retail Pharmacies
          • 5.3.1.2.2.3. Online Pharmacies
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Major Depressive Disorder Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Major Depressive Disorder Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Major Depressive Disorder Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Major Depressive Disorder Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Epidemiology and Patient Population

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals
  • 18.3. Pipeline Overview

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Viatris Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 21.3.2. AbbVie Inc.
    • 21.3.3. Abbott Laboratories
    • 21.3.4. Aurobindo Pharma, Inc.
    • 21.3.5. Teva Pharmaceuticals, Inc.
    • 21.3.6. Sun Pharmaceuticals Industries Ltd.
    • 21.3.7. Pfizer Inc.
    • 21.3.8. Eli Lilly and Company
    • 21.3.9. Otsuka Pharmaceutical Co., Ltd.
    • 21.3.10. Takeda Pharmaceuticals Company Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 3. Global Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 4. Global Major Depressive Disorder Market Share (%), By Region, 2017-2031F
  • Figure 5. North America Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 6. North America Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 7. North America Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 8. North America Major Depressive Disorder Market Share (%), By Country, 2017-2031F
  • Figure 9. United States Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. United States Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 11. United States Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 12. Canada Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 13. Canada Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 14. Canada Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 15. Mexico Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. Mexico Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 17. Mexico Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 18. Europe Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 19. Europe Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 20. Europe Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 21. Europe Major Depressive Disorder Market Share (%), By Country, 2017-2031F
  • Figure 22. Germany Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 23. Germany Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 24. Germany Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 25. France Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 26. France Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 27. France Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 28. Italy Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Italy Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 30. Italy Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 31. United Kingdom Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. United Kingdom Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 33. United Kingdom Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 34. Russia Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 35. Russia Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 36. Russia Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 37. Netherlands Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 38. Netherlands Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 39. Netherlands Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 40. Spain Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Spain Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 42. Spain Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 43. Turkey Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 44. Turkey Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 45. Turkey Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 46. Poland Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Poland Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 48. Poland Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 49. South America Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 50. South America Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 51. South America Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 52. South America Major Depressive Disorder Market Share (%), By Country, 2017-2031F
  • Figure 53. Brazil Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. Brazil Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 55. Brazil Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 56. Argentina Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 57. Argentina Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 58. Argentina Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 59. Asia-Pacific Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 60. Asia-Pacific Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 61. Asia-Pacific Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 62. Asia-Pacific Major Depressive Disorder Market Share (%), By Country, 2017-2031F
  • Figure 63. India Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 64. India Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 65. India Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 66. China Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 67. China Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 68. China Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 69. Japan Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Japan Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 71. Japan Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 72. Australia Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 73. Australia Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 74. Australia Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 75. Vietnam Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 76. Vietnam Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 77. Vietnam Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 78. South Korea Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 79. South Korea Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 80. South Korea Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 81. Indonesia Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Indonesia Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 83. Indonesia Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 84. Philippines Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 85. Philippines Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 86. Philippines Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 87. Middle East & Africa Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 88. Middle East & Africa Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 89. Middle East & Africa Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 90. Middle East & Africa Major Depressive Disorder Market Share (%), By Country, 2017-2031F
  • Figure 91. Saudi Arabia Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 92. Saudi Arabia Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 93. Saudi Arabia Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 94. UAE Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. UAE Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 96. UAE Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 97. South Africa Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 98. South Africa Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 99. South Africa Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. By Drug Classes Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 101. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 102. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023